Code |
Title |
–
|
Top Categories
|
3 |
Administration
|
3E |
Physiological Systems and Anatomical Regions
|
3E0
|
Introduction
Administration, Physiological Systems and Anatomical Regions, Introduction
|
3E06 |
Central Artery
|
3E060 |
Open
|
3E0600 |
Antineoplastic
|
3E06002
|
High-dose Interleukin-2
Introduction of High-dose Interleukin-2 into Central Artery, Open Approach
|
3E06003
|
Low-dose Interleukin-2
Introduction of Low-dose Interleukin-2 into Central Artery, Open Approach
|
3E06005
|
Other Antineoplastic
Introduction of Other Antineoplastic into Central Artery, Open Approach
|
3E0600M
|
Monoclonal Antibody
Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Open Approach
|
3E0600P
|
Clofarabine
Introduction of Clofarabine into Central Artery, Open Approach
|
3E0601 |
Thrombolytic
|
3E06016
|
Recombinant Human-activated Protein C
Introduction of Recombinant Human-activated Protein C into Central Artery, Open
|
3E06017
|
Other Thrombolytic
Introduction of Other Thrombolytic into Central Artery, Open Approach
|
3E0602 |
Anti-infective
|
3E06028
|
Oxazolidinones
Introduction of Oxazolidinones into Central Artery, Open Approach
|
3E06029
|
Other Anti-infective
Introduction of Other Anti-infective into Central Artery, Open Approach
|
3E0603 |
Anti-inflammatory
|
3E0603Z
|
No Qualifier
Introduction of Anti-inflammatory into Central Artery, Open Approach
|
3E0604 |
Serum, Toxoid and Vaccine
|
3E0604Z
|
No Qualifier
Introduction of Serum, Toxoid and Vaccine into Central Artery, Open Approach
|
3E0606 |
Nutritional Substance
|
3E0606Z
|
No Qualifier
Introduction of Nutritional Substance into Central Artery, Open Approach
|
3E0607 |
Electrolytic and Water Balance Substance
|
3E0607Z
|
No Qualifier
Introduction of Electrolytic and Water Balance Substance into Central Artery, Open Approach
|
3E060F |
Intracirculatory Anesthetic
|
3E060FZ
|
No Qualifier
Introduction of Intracirculatory Anesthetic into Central Artery, Open Approach
|
3E060G |
Other Therapeutic Substance
|
3E060GC
|
Other Substance
Introduction of Other Therapeutic Substance into Central Artery, Open Approach
|
3E060GN
|
Blood Brain Barrier Disruption
Introduction of Blood Brain Barrier Disruption Substance into Central Artery, Open Approach
|
3E060H |
Radioactive Substance
|
3E060HZ
|
No Qualifier
Introduction of Radioactive Substance into Central Artery, Open Approach
|
3E060K |
Other Diagnostic Substance
|
3E060KZ
|
No Qualifier
Introduction of Other Diagnostic Substance into Central Artery, Open Approach
|
3E060N |
Analgesics, Hypnotics, Sedatives
|
3E060NZ
|
No Qualifier
Introduction of Analgesics, Hypnotics, Sedatives into Central Artery, Open Approach
|
3E060P |
Platelet Inhibitor
|
3E060PZ
|
No Qualifier
Introduction of Platelet Inhibitor into Central Artery, Open Approach
|
3E060R |
Antiarrhythmic
|
3E060RZ
|
No Qualifier
Introduction of Antiarrhythmic into Central Artery, Open Approach
|
3E060T |
Destructive Agent
|
3E060TZ
|
No Qualifier
Introduction of Destructive Agent into Central Artery, Open Approach
|
3E060V |
Hormone
|
3E060VG
|
Insulin
Introduction of Insulin into Central Artery, Open Approach
|
3E060VH
|
Human B-type Natriuretic Peptide
Introduction of Human B-type Natriuretic Peptide into Central Artery, Open Approach
|
3E060VJ
|
Other Hormone
Introduction of Other Hormone into Central Artery, Open Approach
|
3E060W |
Immunotherapeutic
|
3E060WK
|
Immunostimulator
Introduction of Immunostimulator into Central Artery, Open
|
3E060WL
|
Immunosuppressive
Introduction of Immunosuppressive into Central Artery, Open
|
3E060X |
Vasopressor
|
3E060XZ
|
No Qualifier
Introduction of Vasopressor into Central Artery, Open Approach
|
3E063 |
Percutaneous
|
3E0630 |
Antineoplastic
|
3E06302
|
High-dose Interleukin-2
Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach
|
3E06303
|
Low-dose Interleukin-2
Introduction of Low-dose Interleukin-2 into Central Artery, Percutaneous Approach
|
3E06305
|
Other Antineoplastic
Introduction of Other Antineoplastic into Central Artery, Percutaneous Approach
|
3E0630M
|
Monoclonal Antibody
Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Percutaneous Approach
|
3E0630P
|
Clofarabine
Introduction of Clofarabine into Central Artery, Percutaneous Approach
|
3E0631 |
Thrombolytic
|
3E06316
|
Recombinant Human-activated Protein C
Introduction of Recombinant Human-activated Protein C into Central Artery, Percutaneous
|
3E06317
|
Other Thrombolytic
Introduction of Other Thrombolytic into Central Artery, Percutaneous Approach
|
3E0632 |
Anti-infective
|
3E06328
|
Oxazolidinones
Introduction of Oxazolidinones into Central Artery, Percutaneous Approach
|
3E06329
|
Other Anti-infective
Introduction of Other Anti-infective into Central Artery, Percutaneous Approach
|
3E0633 |
Anti-inflammatory
|
3E0633Z
|
No Qualifier
Introduction of Anti-inflammatory into Central Artery, Percutaneous Approach
|
3E0634 |
Serum, Toxoid and Vaccine
|
3E0634Z
|
No Qualifier
Introduction of Serum, Toxoid and Vaccine into Central Artery, Percutaneous Approach
|
3E0636 |
Nutritional Substance
|
3E0636Z
|
No Qualifier
Introduction of Nutritional Substance into Central Artery, Percutaneous Approach
|
3E0637 |
Electrolytic and Water Balance Substance
|
3E0637Z
|
No Qualifier
Introduction of Electrolytic and Water Balance Substance into Central Artery, Percutaneous Approach
|
3E063F |
Intracirculatory Anesthetic
|
3E063FZ
|
No Qualifier
Introduction of Intracirculatory Anesthetic into Central Artery, Percutaneous Approach
|
3E063G |
Other Therapeutic Substance
|
3E063GC
|
Other Substance
Introduction of Other Therapeutic Substance into Central Artery, Percutaneous Approach
|
3E063GN
|
Blood Brain Barrier Disruption
Introduction of Blood Brain Barrier Disruption Substance into Central Artery, Percutaneous Approach
|
3E063H |
Radioactive Substance
|
3E063HZ
|
No Qualifier
Introduction of Radioactive Substance into Central Artery, Percutaneous Approach
|
3E063K |
Other Diagnostic Substance
|
3E063KZ
|
No Qualifier
Introduction of Other Diagnostic Substance into Central Artery, Percutaneous Approach
|
3E063N |
Analgesics, Hypnotics, Sedatives
|
3E063NZ
|
No Qualifier
Introduction of Analgesics, Hypnotics, Sedatives into Central Artery, Percutaneous Approach
|
3E063P |
Platelet Inhibitor
|
3E063PZ
|
No Qualifier
Introduction of Platelet Inhibitor into Central Artery, Percutaneous Approach
|
3E063R |
Antiarrhythmic
|
3E063RZ
|
No Qualifier
Introduction of Antiarrhythmic into Central Artery, Percutaneous Approach
|
3E063T |
Destructive Agent
|
3E063TZ
|
No Qualifier
Introduction of Destructive Agent into Central Artery, Percutaneous Approach
|
3E063V |
Hormone
|
3E063VG
|
Insulin
Introduction of Insulin into Central Artery, Percutaneous Approach
|
3E063VH
|
Human B-type Natriuretic Peptide
Introduction of Human B-type Natriuretic Peptide into Central Artery, Percutaneous Approach
|
3E063VJ
|
Other Hormone
Introduction of Other Hormone into Central Artery, Percutaneous Approach
|
3E063W |
Immunotherapeutic
|
3E063WK
|
Immunostimulator
Introduction of Immunostimulator into Central Artery, Percutaneous
|
3E063WL
|
Immunosuppressive
Introduction of Immunosuppressive into Central Artery, Percutaneous
|
3E063X |
Vasopressor
|
3E063XZ
|
No Qualifier
Introduction of Vasopressor into Central Artery, Percutaneous Approach
|